Skip to main content

Table 2 Clinical evaluation committee classification of causative microorganisms in community-acquired pneumonia patients

From: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

  Tifacogin
n = 251
Placebo
N = 245
Organism identified Number (percentage) Mortality, number (percentage) Number (percentage) Mortality, number (percentage)
Streptococcus pneumoniae 69 (27.5) 14 (20.3) 70 (28.6) 19 (27.1)
Staphylococcus aureus 33 (13.1) 14 (42.4) 19 (7.8) 12 (63.2)
Haemophilus influenzae 26 (10.4) 5 (19.2) 10 (4.1) 5 (50)
Other respiratory organisms 24 (9.6) 9 (37.5) 23 (9.4) 6 (26.1)
Enteric Gram-negative 20 (8.0) 6 (30) 16 (6.5) 9 (56.3)
Gram stain only 9 (3.6) 3 (33.3) 9 (3.7) 4 (44.4)
Legionella species 6 (2.4) 1 (16.7) 10 (4.1) 2 (20)
Pseudomonas aeruginosa 6 (2.4) 1 (16.7) 12 (4.9) 5 (41.7)
Respiratory viruses 2 (0.8) 1 (50) 0 0
Chlamydophila pneumoniae 0 0 2 (0.8) 0
No organism identified 81 (32.3)   91 (37.1)